Intravenous Magnesium Sulfate May Help Prevent Contrast-Induced Nephropathy

Research suggests that prophylactic use of intravenous magnesium may provide added benefits to traditional hydration for preventing contrast-induced AKI. In a study of 122 patients undergoing percutaneous coronary interventions who were randomized to receive routine treatment or routine treatment plus intravenous magnesium sulfate just before the procedure, contrast-induced AKI occurred in 26.6% of patients in the control group and 14.5% of patients in the study group. There were no deaths or need for hemodialysis in either group in the International Urology and Nephrology study.